MYD Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
High & Stable Gross MarginsSustained ~69% gross margins provide a durable structural advantage in molecular diagnostics, enabling funding of R&D and commercial expansion without immediate margin pressure. High gross margins support eventual operating leverage as revenues scale and help protect adjusted EBITDA targets against volume fluctuations.
Revenue Re-acceleration & Hereditary GrowthA strong revenue re-acceleration and double-digit hereditary testing volume growth indicate durable demand and market-share gains in core markets. Recurring clinician ordering and penetration into both affected and unaffected populations create a structurally larger and stickier revenue base over the medium term.
Deep Product Pipeline & Commercial InvestmentA multi-product launch roadmap (MRD, Prolaris+AI, FirstGene) plus material commercial investment and healthy capital runway are structural growth enablers. If launches achieve clinical and payer adoption, they expand addressable markets and diversify revenue beyond hereditary testing, supporting durable top-line expansion.
Bears Say
Persistent Losses & Negative Free Cash FlowLarge, persistent losses and negative free cash flow erode equity and constrain strategic flexibility. Reliance on balance-sheet capacity raises dilution or refinancing risk, limits discretionary spending, and means profitable scale must be achieved to sustain operations without recurring external funding.
Elevated Opex From Commercial Ramp; Timing RiskSubstantial upfront commercial hiring and higher opex create a timing mismatch: expenses accrue before new hires reach productivity. This execution timing risk can delay forecasted back-half revenue gains, pressuring adjusted EBITDA and requiring sustained capital if ramp underperforms expectations.
Prenatal Business Weakness & Operational DisruptionA notable prenatal revenue decline and lost accounts from system disruption indicate operational and retention weaknesses. Weakness in this business reduces revenue diversification, undermines short-to-medium-term stability, and signals execution gaps that must be fixed to restore provider confidence and volumes.
Myriad Genetics News
MYD FAQ
What was Myriad Genetics’s price range in the past 12 months?
Currently, no data Available
What is Myriad Genetics’s market cap?
Myriad Genetics’s market cap is CHF465.70M.
When is Myriad Genetics’s upcoming earnings report date?
Myriad Genetics’s upcoming earnings report date is Jul 30, 2026 which is in 19 days.
How were Myriad Genetics’s earnings last quarter?
Myriad Genetics released its earnings results on May 05, 2026. The company reported -$0.073 earnings per share for the quarter, missing the consensus estimate of -$0.055 by -$0.018.
Is Myriad Genetics overvalued?
According to Wall Street analysts Myriad Genetics’s price is currently Undervalued.
Does Myriad Genetics pay dividends?
Myriad Genetics does not currently pay dividends.
What is Myriad Genetics’s EPS estimate?
Myriad Genetics’s EPS estimate is -0.05.
How many shares outstanding does Myriad Genetics have?
Currently, no data Available
What happened to Myriad Genetics’s price movement after its last earnings report?
Myriad Genetics reported an EPS of -$0.073 in its last earnings report, missing expectations of -$0.055. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Myriad Genetics?
Currently, no hedge funds are holding shares in CH:MYD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Myriad Genetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
CHF6.02 (― Downside)
CHF6.02 (― Downside)
Insider Transactions
Bought Shares
Worth CHF22.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
6.64%
12-Months-Change
Fundamentals
Return on Equity
-109.09%
Trailing 12-Months
Asset Growth
-33.04%
Trailing 12-Months
Company Description
Myriad Genetics
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
MYD Company Deck
MYD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized meaningful progress in core growth engines (double-digit hereditary cancer growth, robust GeneSight performance, solid gross margins and a deep product pipeline) and management reaffirmed full-year guidance and positive adjusted EBITDA expectations. Near-term pressures include a Q1 adjusted EBITDA loss, higher operating expense due to accelerated commercial hiring, and a notable prenatal revenue decline. Management is investing to drive back-half acceleration but execution (sales ramp, MRD adoption, payer reimbursement) will determine pace of recovery. On balance, the positives around market share gains, product launches and revenue guidance outweigh the short-term profitability and prenatal headwinds.View all CH:MYD earnings summariesMYD Stock 12 Month Forecast
Average Price Target
$6.02
Options Prices
Currently, No data available
---